Groupe d'Etude en Oncologie du Quebec

Titre	A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234
Protocole ID	IND.234B
ClinicalTrials.gov ID	NCT03385655
Type(s) de cancer	Prostate
Phase	Phase II
Médicament	Savolitinib
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	Montréal
Investigateur(trice) principal(e)	Dr Fred Saad
Coordonnateur(trice)	Amal Nadiri 514-890-8000 poste 26074
Statut	Actif en recrutement
Critètes d'éligibilité	Patients must meet the following criteria in addition to the eligiblity criteria outlined in IND.234. Men of childbearing potential must have agreed to use a highly effective contraceptive method during Study Drug treatment and for 6 months after stopping treatment and should not father a child or donate sperm during this period. Patients with significantly abnormal liver diseases including viral/other hepatitis, current alcohol abuse or cirrhosis are not eligible. Patients in whom strong inducers or inhibitors of CYP3A4 and strong inhibitors of CYP1A2 cannot be discontinued within 2 weeks before the first dose of savolitinib (3 weeks for St John's Wort) are not eligible.
Critètes d'exclusion

Groupe d'étude en oncologie du Québec